Seattle Genetics and its development partner Takeda recently announced stellar Phase III data from its ECHELON-2 clinical trial of Adcetris for peripheral T-cell lymphoma. Clay Siegall, president and CEO of Seattle Genetics, took time to speak with BioSpace about the approval and plans for the drug.
